erythropoetin beta
ApprovedSmall molecule
erythropoetin beta is one of 15 small molecule programs targeting Ischemic Cardiomyopathy. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
27 competitors in Ischemic Cardiomyopathy
#DrugCompanyPhaseTrials
1Calan
VVal Adams
Approved
Atorvastatin Calcium
Merck & Co.Approved
Steglatro
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
RANEXA
GileadApproved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
erythropoetin beta
CCharite University, Berlin, Germany
Approved
Aldactone
PfizerPreclinical
Victoza
Novo NordiskPreclinical
Zinc Acetate
NNobelpharma
Phase 1
Mesenchymal Stem Cells
JJiangsu Topcel-KH Pharmaceutical Co., Ltd.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Ischemic Cardiomyopathy1 trial
Chronic, Low Dose Erythropoetin Beta in Ischemic Cardiomyopathy
Completed·—·Phase 4·NCT00568542·28 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for erythropoetin beta. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details